BiDAC

Home Tag

Copia de Copia de Copia de Banner web VHIO (12)

Preliminary results from a first-in-human phase 1/2 trial show promise of novel BiDAC ™ degrader designed to overcome treatment resistance in solid tumors

Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…